A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma

被引：2

作者：

Ali, Meser M. ^{[1
]}

Bhuiyan, Mohammed P. I. ^{[1
]}

Janic, Branislava ^{[1
]}

Varma, Nadimpalli R. S. ^{[1
]}

Mikkelsen, Tom ^{[1
]}

Ewing, James R. ^{[1
]}

Knight, Robert A. ^{[1
]}

Pagel, Mark D. ^{[2
]}

Arbab, Ali S. ^{[1
]}

机构：

[1] Henry Ford Hosp, Detroit, MI 48202 USA

[2] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA

来源：

NANOMEDICINE | 2012年 / 7卷 / 12期

关键词：

brain tumor; contrast agent; dendrimer; MRI; pharmacokinetic; EXCHANGE SATURATION-TRANSFER; REDUNDANT DEVIATION; BRAIN TEMPERATURE; PH; SHIFTS;

D O I：

10.2217/NNM.12.92

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Aim: The authors have investigated the usefulness of in vivo chemical exchange saturation transfer MRI for detecting gliomas using a dual-modality imaging contrast agent. Materials & methods: A paramagnetic chemical exchange saturation transfer MRI contrast agent, Eu-1,4,7,10-tetraazacclododecane-1,4,7,10-tetraacetic acid-Gly(4) and a fluorescent agent, DyLight (R) 680, were conjugated to a generation 5 polyamidoamine dendrimer to create the dual-modality, nano-sized imaging contrast agent. Results: The agent was detected with in vivo chemical exchange saturation transfer MRI in an U87 glioma model. These results were validated using in vivo and ex vivo fluorescence imaging. Conclusion: This study demonstrated the merits of using a nano-sized imaging contrast agent for detecting gliomas and using a dual-modality agent for detecting gliomas at different spatial scales. Original submitted 9 January 2012; Revised submitted 18 April 2012; Published online 14 August 2012

引用

页码：1827 / 1837

页数：11